drugset / Trial / NCT02552342
Corticosteroid Therapy for Severe Community-Acquired Pneumonia
Phase 4
Unknown
610 enrolled
Peking Union Medical College Hospital
Affiliated Hospital of Hebei University · collabCangzhou Central Hospital · collabCangzhou People's Hospital · collabFirst Affiliated Hospital of Wenzhou Medical University · collabJinhua Central Hospital · collabNantong University · collabNavy General Hospital, Beijing · collabNorthern Jiangsu People's Hospital · collabTaishan Medical University Affiliated Hospital · collabThe First Affiliated Hospital of Anhui Medical University · collabThe Second Hospital of Hebei Medical University · collabTianjin Medical University General Hospital · collabTianjin Third Central Hospital · collabZhejiang University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the present study is to assess the efficacy of methylprednisolone as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (PSI 4-5). The hypothesis of the study is that methylprednisolone can decrease the mortality of severe CAP without any significant side effects,with reduction of the time to clinical stability and failure rate of treatment.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methylprednisolone | Other / unclassified | 40 mg | — |
Indications
No indication recorded.